MedTrace Logo

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

NCT04802980 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2021-07-28

No results posted yet for this study

Summary

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T in combination with different chemotherapy regimens administered to patients with advanced solid tumors.

Conditions

Interventions

DRUG

HB002.1T

HB002.1T is a vascular endothelial growth factor receptor decoy

DRUG

Oxaliplatin

Oxaliplatin is an anti-tumor drug

DRUG

Capecitabine

Capecitabine is an anti-tumor drug

DRUG

Paclitaxel

Paclitaxel is an anti-tumor drug

DRUG

Gemcitabine

Gemcitabine is an anti-tumor drug

DRUG

Cisplatin

Cisplatin is an anti-tumor drug

DRUG

Carboplatin

Carboplatin is an anti-tumor drug

Sponsors & Collaborators

  • Huabo Biopharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jin Li, Ph.D · Shanghai East Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2023-07-15
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04802980 on ClinicalTrials.gov